COVID-19: Swedish company is awarded prestigious grant

In strong competition GAEU’s client Vicore Pharma Holding AB (publ) was awarded £ 1.5 million by the British charity LifeArc for a COVID-19 Phase II study with the drug candidate VP01. The study, named ATTRACT (Angiotensin II Type Two Receptor Agonist COVID-19 Trial), is targeting hospitalized patients treated with basic respiratory care, but not yet on mechanical ventilation. In close cooperation between the GAEU’s and Vicore’s team, the winning application was written in record time. 

Johan Raud, MD, PhD, Chief Scientific Officer, Vicore Pharma Holding AB (publ):

“We had less than a week to complete this application, and from previous experience of working with GAEU, we knew that they were the right partner for us. By working intensively in a highly interactive and efficient state of flow, we generated a strong application in just 4 days, including a weekend. I’m impressed by their skills and how fast they grasped the essence of our rather complex project. They are not only dedicated, they are also pleasurable to work with. I look forward to working with them again.”

More information:

Roland Vilhelmsson, CEO GAEU Consulting AB, +46 70-205 87 29, roland.vilhelmsson@gaeu.se

Johan Raud, Vicore Pharma Holding AB (publ), +46 733 501 665 johan.raud@vicorepharma.com, Vicorepharma.com

Pictures for free publication can be found in our press room at www.gaeu.com

To meet global challenges in areas such as health, the environment and communication, the world's leaders have committed themselves to achieving the Global Goals by 2030. GAEU's mission is to contribute to the emergence of innovative solutions that will change the world for the better. We do this by helping innovation companies to fund their growth. We have Sweden's longest reference list when it comes to applications for the H2020 SME Instrument and the EIC Accelerator Pilot.